Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

TriLink’s grant win boosts dNTP investigation

TriLink BioTechnologies : 08 May, 2008  (Company News)
TriLink BioTechnologies has been awarded a $750,000 Phase II Small Business Innovation Research (SBIR) grant to continue its investigation of modified dNTPs to improve the fidelity of PCR reactions.
Phase I studies demonstrated that TriLink's dNTP modifications enhanced PCR performance by increasing amplicon formation while reducing off-target amplicon formation. In the second phase of the programme, TriLink will look to further expand upon Phase I studies to develop novel solutions for endpoint PCR, real-time PCR, multiplex PCR, fast PCR, and more advanced PCR applications.

TriLink will also optimise the synthetic route for scale-up of the modified dNTPs and will develop robust PCR Assay recommendations in preparation for commercialisation of the technology in early 2009. This is the third Phase II grant TriLink has been awarded.

'We believe that this novel approach to improving PCR fidelity complements our CleanAmp product line very nicely,' said Dr Richard Hogrefe, chief executive officer and president of TriLink. 'Now we offer modified primers and modified dNTPs. The CleanAmp Primers will solve specific Assay issues whereas the modified dNTPs will be a more general solution. Either product will provide a very cost effective solution when compared to the modified enzymes available on the market.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo